GlassScriptPhysician profile
Sean E Smithey
NPI 1487835401
$605.27
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $40.05 · 2023: $248 · 2024: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $63.47 | 2023-2024 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.06 | 2022-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $50.05 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.79 | 2023-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $46.71 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $39.23 | 2023-2024 | Farxiga |
| Xeris Pharmaceuticals, INC. | $36.15 | 2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $35.99 | 2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $32.17 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $26.91 | 2023 | Inpefa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.66 | 2024 | Caplyta |
| Scpharmaceuticals INC. | $21.49 | 2024 | |
| Novo Nordisk INC | $20.44 | 2024 | Rybelsus, Ozempic |
| Baxter Healthcare | $20.23 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $19.22 | 2023 | Xarelto |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $16.16 | 2024 | Voquezna |
| Amphastar Pharmaceuticals, INC. | $15.46 | 2024 | |
| Amgen INC. | $14.96 | 2024 | Repatha, Otezla |
| Pfizer INC. | $13.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Smithey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.